Abstract
Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it’s associated with HF with preserved ejection fraction (HFPEF).
Keywords: Biomarker, heart failure, parathyroid hormone.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Volume: 13 Issue: 1
Author(s): Hakan Altay and Yucel Colkesen
Affiliation:
Keywords: Biomarker, heart failure, parathyroid hormone.
Abstract: Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it’s associated with HF with preserved ejection fraction (HFPEF).
Export Options
About this article
Cite this article as:
Altay Hakan and Colkesen Yucel, Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010012
DOI https://dx.doi.org/10.2174/1871530311313010012 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity and Body Composition in Man and Woman: Associated Diseases and the New Role of Gut Microbiota
Current Medicinal Chemistry Caveolae and Caveolins in the Respiratory System
Current Molecular Medicine Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Impact of Metabolic Surgery on Type-2 Diabetes Remission
Current Diabetes Reviews Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats
Drug Metabolism Letters Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment
Current Cancer Drug Targets Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism
Current Diabetes Reviews Coronary Microcirculation in Heart Failure with Preserved Systolic Function
Current Pharmaceutical Design Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Characterization of a Novel Polysaccharide-Iron(III) Complex and Its Anti-Anemia and Nonspecific Immune Regulating Activities
Mini-Reviews in Medicinal Chemistry Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry The Effect of Modified-Release Ketoconazole on Insulin Resistance in Patients with Severe Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)